Trump Ties 340B To High Prices, Asks For Feedback On Changing Program

May 11, 2018
President Donald Trump's drug price containment plan blames the 340B drug discount program in part for high drug prices, and asks for feedback in a number of areas including how the program's growth affects list prices and insurers, whether the definition of a 340B patient should be changed and how to better prohibit duplicate discounts. Both the definition of a patient and duplicate discounts were covered in guidance initially published by the Obama administration that Trump's Health Resources and Services...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, news from FDA and much more.